Pharmacological treatment
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: The study will include patients diagnosed with CA of the digestive system aged 18 years or older undergoing intravenous antineoplastic chemotherapy treated at the HC / UFTM chemotherapy service. To this end, they agreed to participate in the study by signing the Informed Consent Form, as well as the Free Informed Consent Form prepared according to Resolution 466/12 of the National Health Council (BRAZIL, 2012).
Exclusion criteria
Exclusion criteria: Will be excluded from the study patients who underwent antineoplastic chemotherapy treatment and / or previous radiotherapy; in adjuvant radiotherapy treatment; diagnosis of metastatic AC, which will perform less than three treatment cycles and / or change chemotherapy protocol during the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| It is expected to find a reduction and / or a better fatigue score in the intervention group compared to the control group, verified by the Piper Fatigue Scale, the results are presented by percentages used to verify if the outcome actually occurred | — |
Secondary
| Measure | Time frame |
|---|---|
| It is expected to find an increase and / or better quality of life score in the intervention group compared to the control group, to be evaluated by the EORTC-QLQ-C30, the results will be presented by percentages used to verify if the outcome actually occurred | — |
Countries
Brazil
Contacts
Universidade Federal do Triângulo Mineiro